Navigation Links
EntreMed Secures $10 Million Strategic Financing
Date:1/23/2012

es in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.

About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About IDG-Accel Fund
IDG-Accel Fund is a private equity investment fund focused on investment in various sectors and is managed by IDG Capital Partners, a leading investment management team in China with over 18-years of investment experience and industry knowledge.

Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operati
'/>"/>

SOURCE EntreMed
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 ... and marketer of innovative medical devices for the treatment of ... prevailed in a final opposition appeal hearing in the European ... - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent has ... has been upheld as a valid patent in amended form. ...
(Date:7/1/2015)... , July 1, 2015  MEI Pharma, Inc. (Nasdaq: ... development of novel therapies for cancer, announced today that ... will present at the inaugural Cantor Fitzgerald Healthcare Conference on ... Le Parker Meridien in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:7/1/2015)... Lupin , ... Number of MPP Sub-licensees to Fourteen Companies   ... the rapid expansion of its network of generic manufacturers to ... develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and Strides Arcolab ... HIV medicine the MPP licensed from ViiV Healthcare two months ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3
... Corporation (Nasdaq: DYNT ) announced that it ... Portfolio, a group of companies selected by RB Milestone ... via a combination of traditional and innovative analytical and ... non-deal roadshows, with a focus on the healthcare, mining, ...
... 2011 The U.S. Food and Drug Administration and ... pilot program that will allow parallel evaluation of relevant ... Design (QbD), of new drug marketing applications that are ... ) The parallel evaluation within this ...
Cached Medicine Technology:Dynatronics Selected for Inclusion in RB Milestone Portfolio 2FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications 2FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications 3
(Date:7/2/2015)... ... ... Every year, DUI arrests and fatalities spike on the 4th of July. In fact, because ... when it comes to being on the road. According to attorney David J. Maloney ... of all highway deaths between 2007 and 2011 were caused by drunk driving over the ...
(Date:7/2/2015)... ... , ... no secret that what we consume can have an effect on the body. And during the ... or perhaps even undernourished if not eating enough of the right foods, as well as drinking ... of year to overdo it on the food front as well, with sweet treats like ice ...
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, ... Semiconductor Timing announced the release and publication of their newest offering to complement ... publication and Newsletter. , Designed in support of coverage for the full ...
(Date:7/1/2015)... Los Angeles, CA (PRWEB) , ... July 01, 2015 , ... ... enjoy the great outdoors. Yet, in many Middle-Eastern countries like Saudi Arabia and Dubai, ... entirely to relax in more temperate climates. Celebrity dentist Dr. Sam Saleh of ORA ...
(Date:7/1/2015)... York, New York (PRWEB) , ... July 01, ... ... injury lawsuit filed against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted ... U.S. District Court, Southern District of West Virginia on June 26th, the Court ...
Breaking Medicine News(10 mins):Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... In-Q-Tel Investment in Sonitus Medical Accelerates Development of ... the TeethSAN MATEO, Calif., May 26 Sonitus ... world,s first non-surgical and removable hearing device to ... strategic investment and technology advancement agreement with In-Q-Tel, ...
... on the cholesterol-lowering drugs , , MONDAY, May 25 (HealthDay News) ... risk of a second stroke, new research shows. , The ... a 35 percent lower incidence of second strokes and a ... compared to those who didn,t, according to a report in ...
... the L.A. MarathonLOS ANGELES, May 25 Today,s Los Angeles ... infamous and hugely-plumped characters from the Foster Farms television commercials. ... pass themselves off as fresh, natural and never "plumped" Foster ... entered the duo as part of its "Say No To ...
... Vienna, Austria: The relationship between the dental disease ... for several years. Although a genetic link ... Now, for the first time, scientists have discovered a ... the annual conference of the European Society of Human ...
... of trials finds Avastin with chemo doubles odds ... of the drug bevacizumab (Avastin) in combination with chemotherapy ... patients, new research has found. , These perforations are ... small intestine or large bowel. , Bevacizumab is designed ...
... woman,s death in New York City raises national toll to ... been made towards developing a viable H1N1 swine flu vaccine, ... Prevention saying this week that they have two promising candidate ... 50-year-old woman died of swine flu in New York City ...
Cached Medicine News:Health News:Sonitus Medical Secures Strategic Investment and Technology Advancement Agreement From In-Q-Tel 2Health News:Sonitus Medical Secures Strategic Investment and Technology Advancement Agreement From In-Q-Tel 3Health News:Statins Can Help Prevent Second Stroke 2Health News:Statins Can Help Prevent Second Stroke 3Health News:Scientists find shared genetic link between the dental disease periodontitis and heart attack 2Health News:Cancer Drug May Boost Risk of Gastrointestinal Perforation 2Health News:Viable Swine Flu Shot Closer to Reality 2Health News:Viable Swine Flu Shot Closer to Reality 3Health News:Viable Swine Flu Shot Closer to Reality 4Health News:Viable Swine Flu Shot Closer to Reality 5Health News:Viable Swine Flu Shot Closer to Reality 6Health News:Viable Swine Flu Shot Closer to Reality 7Health News:Viable Swine Flu Shot Closer to Reality 8Health News:Viable Swine Flu Shot Closer to Reality 9Health News:Viable Swine Flu Shot Closer to Reality 10Health News:Viable Swine Flu Shot Closer to Reality 11Health News:Viable Swine Flu Shot Closer to Reality 12Health News:Viable Swine Flu Shot Closer to Reality 13
Chemically Resistant Sealing Mat for 96ch, 1.1ml or 2.0ml, Deep Well, Round Available Sterile...
Sealing Mat for 96-well PCR Plate, Natural...
MicroAmp Full Plate Covers, which are manufactured from PCR-compatible rubber, are non-sterile, autoclavable and guaranteed reusable up to five times....
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Medicine Products: